Tomas Chao, PA
Medical · Woodstock, GANPI 1316003577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,412,287 of the $1,880,617 with a category attached, or 75.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.0%. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,630 payments — averaging $518.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$395K
- AbbVie$272K
- Johnson & Johnson$233K
- UCB, Inc.$204K
- Arcutis Biotherapeutics, Inc.$92K
- Dermavant Sciences, Inc.$84K
- plus $601K from 28 others
What the payments were for
- Consulting fees$207,04011%
- Speaking & faculty fees$1,412,28775%
- Travel & lodging$203,36611%
- Food & beverage$57,2843%
- Education$6390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 699 | $394,551 |
| AbbVie | 529 | $271,930 |
| Johnson & Johnson | 327 | $232,920 |
| UCB, Inc. | 323 | $203,622 |
| Arcutis Biotherapeutics, Inc. | 196 | $92,432 |
| Dermavant Sciences, Inc. | 160 | $84,249 |
| Incyte Corporation | 179 | $80,214 |
| Regeneron Healthcare Solutions, Inc. | 165 | $77,420 |
| Janssen Scientific Affairs, LLC | 91 | $72,319 |
| E.r. Squibb & Sons, L.L.C. | 137 | $69,037 |
| Sanofi | 136 | $66,692 |
| Amgen | 82 | $42,014 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 142 | $41,887 |
| Sun Pharmaceutical Industries Inc. | 77 | $29,874 |
| Organon | 57 | $27,473 |
| LEO Pharma Inc. | 93 | $26,363 |
| Galderma Laboratories, L.p. | 79 | $25,902 |
| Pfizer | 28 | $11,682 |
| VYNE Pharmaceuticals Inc. | 19 | $6,187 |
| Boehringer Ingelheim | 7 | $4,810 |
| Botanix SB Inc | 18 | $4,401 |
| EPI Health, LLC | 7 | $3,822 |
| Kowa Pharmaceuticals America, Inc. | 5 | $3,327 |
| Mayne Pharma Commercial LLC | 20 | $2,877 |
| Novartis | 32 | $2,150 |
| Merz North America, Inc. | 8 | $1,379 |
| Journey Medical Corporation | 2 | $517 |
| Almirall LLC | 3 | $337 |
| Verrica Pharmaceuticals Inc. | 2 | $60 |
| Eli Lilly | 1 | $48 |
| Nabriva Therapeutics, PLC | 2 | $44 |
| Medtronic | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,880,617 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 30 | $616,074 |
| Taltz AutoinjectorIxekizumab | 86 | $584,346 |
| Dupixent PenDupilumab | 90 | $336,698 |
| RinvoqUpadacitinib | 24 | $149,684 |
| SotyktuDeucravacitinib | 12 | $74,103 |
| AdbryTralokinumab-Ldrm | 17 | $66,656 |
| Dupixent SyringeDupilumab | 13 | $47,578 |
| OpzeluraRuxolitinib Phosphate | 12 | $24,730 |
| Clobetasol Propionate | 188 | $8,192 |
| Betamethasone Dipropionate | 108 | $4,740 |
| Doxycycline Hyclate | 168 | $3,120 |
| Ketoconazole | 140 | $2,013 |
| Fluocinonide | 42 | $1,488 |
| Mometasone Furoate | 80 | $1,450 |
| Metronidazole | 29 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $271,930 | $149,68424 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $69,037 | $74,10312 claims |
| LEO Pharma Inc.Adbry | $26,363 | $66,65617 claims |
| Incyte CorporationOpzelura | $80,214 | $24,73012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.
Other medical in Woodstock
- Nicole RiveraWoodstock$10K
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.